CCHT: Clinical trial approval for the domestically produced injectable GenSci139

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, Changchun Gaoxin (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, agreeing to conduct clinical trials of the injectable GenSci139 monotherapy in patients with advanced solid tumors

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.